Payment overview · 2025
General Payments
$19,659.88
99 reported records · 23 companies
Healthcare provider profile · identity verified
Julio E Conrado, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1588624944
Verified facts
What the public records show
CMS Open Payments records show Julio E Conrado, MD received $19,659.88 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 80.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Nucala, Opsumit, Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Uptravi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15,843.48 | 80.6% | 29 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $1,029.89 | 5.2% | 14 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $605.64 | 3.1% | 8 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $379.94 | 1.9% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $333.49 | 1.7% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $234.27 | 1.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.06 | 0.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $157.74 | 0.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $156.22 | 0.8% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.92 | 0.6% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $112.63 | 0.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $102.59 | 0.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $76.21 | 0.4% | 3 | 2025 |
| SPINEFRONTIER, INC. | Unresolved — no canonical attribution shown | $72.64 | 0.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $47.87 | 0.2% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $35.44 | 0.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $34.31 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.85 | 0.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.82 | 0.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.75 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.38 | 0.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $23.58 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.16 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,250.00 | 8 |
| Food and Beverage | $5,218.90 | 88 |
| Travel and Lodging | $173.60 | 2 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15,101.95 | 19 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $567.59 | 6 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $425.48 | 8 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $379.94 | 7 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $333.49 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $306.44 | 5 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $260.52 | 2 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $234.27 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $204.69 | 4 | 2025 |
Source payment records
|
|||||
| Orenitram Normalized: orenitram |
Drug | United Therapeutics Corporation | $178.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $157.74 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $156.22 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $136.90 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $119.92 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $112.63 | 1 | 2025 |
Source payment records
|
|||||
| FacetFUSE Normalized: facetfuse |
Device | SPINEFRONTIER, INC. | $72.64 | 1 | 2025 |
Source payment records
|
|||||
| Inspan Normalized: inspan |
Device | SPINEFRONTIER, INC. | $72.64 | 1 | 2025 |
Source payment records
|
|||||
| NanoFUSE Normalized: nanofuse |
Device | SPINEFRONTIER, INC. | $72.64 | 1 | 2025 |
Source payment records
|
|||||
| SIJFuse Normalized: sijfuse |
Device | SPINEFRONTIER, INC. | $72.64 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $57.93 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $35.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
230 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 625 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 543 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 408 | 131 |
| Prednisone | Prednisone | 374 | 204 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 367 | 165 |
| Losartan Potassium | Losartan Potassium | 336 | 107 |
| Simvastatin | Simvastatin | 336 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 96 |
| Omeprazole | Omeprazole | 285 | 82 |
| Metformin Hcl | Metformin Hcl | 280 | 97 |
| Lisinopril | Lisinopril | 275 | 86 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 230 | 64 |
| Gabapentin | Gabapentin | 227 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 80 |
| Breo Ellipta | Fluticasone/Vilanterol | 199 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 56 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 182 | 52 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 179 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 51 |
| Alprazolam | Alprazolam | 157 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 46 |
| Montelukast Sodium | Montelukast Sodium | 141 | 38 |
| Xarelto | Rivaroxaban | 139 | 36 |
| Metformin Hcl Er | Metformin Hcl | 138 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 39 |
| Atenolol | Atenolol | 118 | 27 |
| Trazodone Hcl | Trazodone Hcl | 118 | 37 |
| Famotidine | Famotidine | 112 | 37 |
| Furosemide | Furosemide | 110 | 45 |
| Clonazepam | Clonazepam | 109 | 30 |
| Azithromycin | Azithromycin | 107 | 86 |
| Ezetimibe | Ezetimibe | 107 | 32 |
| Allopurinol | Allopurinol | 100 | 29 |
| Meloxicam | Meloxicam | 89 | 27 |
| Ozempic | Semaglutide | 89 | 17 |
| Farxiga | Dapagliflozin Propanediol | 88 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 31 |
| Methylprednisolone | Methylprednisolone | 85 | 63 |
| Potassium Chloride | Potassium Chloride | 83 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 80 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 19 |
| Ofev | Nintedanib Esylate | 78 | 12 |
| Temazepam | Temazepam | 77 | 23 |
| Eliquis | Apixaban | 74 | 19 |
| Januvia | Sitagliptin Phosphate | 73 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 55 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 72 | 31 |
| Lorazepam | Lorazepam | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 68 | 25 |
| Glimepiride | Glimepiride | 66 | 21 |
| Bupropion Xl | Bupropion Hcl | 64 | 20 |
| Buspirone Hcl | Buspirone Hcl | 64 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 63 | 18 |
| Ibuprofen | Ibuprofen | 63 | 23 |
| Spiriva Respimat | Tiotropium Bromide | 61 | 19 |
| Carvedilol | Carvedilol | 60 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 47 |
| Jardiance | Empagliflozin | 60 | 15 |
| Tramadol Hcl | Tramadol Hcl | 59 | 20 |
| Torsemide | Torsemide | 58 | 24 |
| Celecoxib | Celecoxib | 57 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 29 |
| Spironolactone | Spironolactone | 50 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 50 | 19 |
| Donepezil Hcl | Donepezil Hcl | 48 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Roflumilast | Roflumilast | 44 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 18 |
| Finasteride | Finasteride | 40 | 13 |
| Fluconazole | Fluconazole | 40 | 27 |
| Baclofen | Baclofen | 38 | suppressed |
| Nucala | Mepolizumab | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 17 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Tyvaso Dpi | Treprostinil | 33 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | 15 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Diazepam | Diazepam | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Desloratadine | Desloratadine | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 21 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Opsumit | Macitentan | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 13 |
| Tadalafil | Tadalafil | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Topiramate | Topiramate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Uptravi | Selexipag | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19,659.88 · 99 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CAPVAXIVE, DUPIXENT, FARXIGA, FacetFUSE, GARDASIL 9, INGREZZA, INSPIRE, Inspan, Intracept, LUMRYZ, MOUNJARO, NUCALA, NUZYRA, NanoFUSE, OPSUMIT, OPSYNVI, Ohtuvayre, Orenitram, Remodulin, SIJFuse, SMARTVEST, TEZSPIRE, Tyvaso, UPTRAVI, VOQUEZNA, WAKIX, WINREVAIR, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error